Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
about
Visceral adiposity index: an indicator of adipose tissue dysfunction.Hyperprolactinaemia - a problem in patients from the reproductive period to the menopause.The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergolineAssociation between serum prolactin levels and insulin resistance in non-diabetic menVisceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma.Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.
P2860
Q33563343-52B0C4D8-B9DD-46E6-8610-1110896E2ED0Q33704842-5AD82152-0756-4643-8835-26FEA86E38A9Q35546563-DDD54147-7059-4F38-AA4F-DA2924E1FCE9Q36292478-34B894CF-53CA-499A-8D60-F7415F799BD0Q36338425-EF10AB9C-6591-4535-B3C7-B5ADFEB89C5CQ39096101-43DB98CF-5076-469B-AB1E-CB84B272DC40Q39180016-7CFBD5C7-6965-4FAE-B54E-003D38A8BE2FQ39336294-3ED39400-5485-490E-BD41-3101E40C258EQ40006452-B005DDFC-9728-4E6A-AC92-224D707EA2E2Q41484984-861CCE37-F56A-4B57-82E3-3F7F9B9015B0Q41610640-BD2CDE3A-F894-4D91-BB8B-873C488590B3Q47230953-757CCDAF-ECD7-452D-A655-6546E990E8BEQ49598291-66E4CD80-794C-453B-A406-468DA57FD009Q51471446-4FBD2421-C8A9-4CA6-BE54-746986BBAA60
P2860
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
type
label
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
prefLabel
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@nl
P2093
P2860
P356
P1476
Higher doses of cabergoline fu ...... reduction in prolactin levels.
@en
P2093
Alessandro Ciresi
Flavia Lo Castro
Marco Calogero Amato
Valentina Guarnotta
P2860
P304
P356
10.1111/CEN.12204
P577
2013-04-22T00:00:00Z